Smolen, J. S., Mease, P., Tahir, H., Schulze-Koops, H., de la Torre, I., Li, L., . . . Nash, P. (2020). Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: Final results by week 52. Ann Rheum Dis.
Stile di citazione ChicagoSmolen, Josef S., et al. "Multicentre, Randomised, Open-label, Parallel-group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Naïve to Biological Disease-modifying Antirheumatic Drug: Final Results By Week 52." Ann Rheum Dis 2020.
Citazione MLASmolen, Josef S., et al. "Multicentre, Randomised, Open-label, Parallel-group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Naïve to Biological Disease-modifying Antirheumatic Drug: Final Results By Week 52." Ann Rheum Dis 2020.